New Drug Shows Promising Results For Psoriatic Arthritis
Wednesday, April 15, 2009 - 20:35
in Health & Medicine
Psoriatic arthritis affects about 11 percent of patients with psoriasis. Anti-tumor necrosis factor ± (anti-TNF±) agents, which block signaling molecules that induce inflammation, improve the symptoms of psoriatic arthritis. Golimumab is a new human monoclonal antibody that works against TNF± and has been shown to be beneficial within two weeks of the first subcutaneous injection in a phase II rheumatoid arthritis trial.
